IP Library Granted Patent US 9,642,905
Granted Patent B2
US 9,642,905 · App. 14/777,672 · Granted May 9, 2017

Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica

Inventor: Antonius Arnoldus Christiaan Jacobs (Kessel, NL)
Assignee: Intervet Inc.
A61K39/102A61K39/155A61K39/265A61K2039/522A61K2039/5254A61K2039/543A61K2039/544A61K2039/552A61K2039/70C12N7/00C12N2710/16734C12N2760/18534C12N2760/18634
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,642,905
App. No.
14/777,672
Granted
May 9, 2017
Kind
B2
Abstract

The present invention pertains to a vaccine for administration to the upper respiratory tract of a ruminant to protect said ruminant against pneumonia caused by Mannheimia haemolytica , the vaccine comprising in combination live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, wherein the vaccine is for administration to the upper respiratory tract of the ruminant via intranasal atomization of the vaccine.

Claims (12)

1. A method to protect a ruminant against pneumonia caused by Mannheimia haemolytica bacteria comprising administering a vaccine to the upper respiratory tract of the ruminant by intranasal atomisation of said vaccine, wherein said vaccine comprises live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus, and live attenuated bovine respiratory syncytial virus.

2. The method of claim 1 , wherein the vaccine further comprises live attenuated infectious bovine rhinotracheitis virus.

3. The method of claim 1 , wherein the atomisation provides a mist of vaccine particles having an average size below 50 μm in diameter.

4. The method of claim 3 , wherein the average vaccine particle size is between 20 and 40 μm in diameter.

5. The method of claim 4 , wherein the vaccine further comprises live attenuated infectious bovine rhinotracheitis virus.

6. The method of claim 3 , wherein the vaccine further comprises live attenuated infectious bovine rhinotracheitis virus.

7. The method of claim 1 , wherein the administration is to bovines at an age of less than 4 weeks.

8. The method of claim 1 , wherein the vaccine is applied by a single administration.

9. The method of claim 8 , wherein the volume of the single administration is divided over both nostrils.

10. The method of claim 3 , wherein the administration is to bovines at an age of less than 4 weeks.

11. The method of claim 3 , wherein the vaccine is applied by a single administration.

12. The method of claim 11 , wherein the volume of the single administration is divided over both nostrils.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2017
From: JACOBS, ANTONIUS ARNOLDUS CHRISTIAAN
To: INTERVET INC.
Reel/Frame 041680/0099 →
Priority Claims (1)
EP 13159665 · Mar 18, 2013 · regional
Continuity (1)
Related Publication 20160287690A1 · Oct 6, 2016